Related Experiment Video
Updated: Jun 18, 2026
08:56
Remote Neuronal Activation Coupled with Automated Blood Sampling to Induce and Measure Circulating Luteinizing Hormone in Mice
Published on: August 25, 2023
Luteinizing hormone-releasing hormone antagonists.
1Eötvös Loránd University, Hungarian Academy of Sciences, Research Group of Peptide Chemistry, Budapest, Pázmány P. stny. 1/A, Hungary. gmezo@elte.hu
Expert Opinion on Therapeutic Patents
|November 27, 2009
Summary
Luteinizing hormone-releasing hormone (LH-RH) antagonists are crucial for vertebrate reproduction and have therapeutic uses. Research is advancing to develop new peptidic and orally active non-peptidic LH-RH antagonists.
Area of Science:
- Reproductive endocrinology
- Oncology
- Pharmacology
Background:
- Luteinizing hormone-releasing hormone (LH-RH) regulates gonadal activity in vertebrates.
- LH-RH receptors are present in the pituitary and on cancer cells, enabling therapeutic targeting.
- LH-RH agonists and antagonists have been developed for various medical applications.
Purpose of the Study:
- To provide an overview of relevant LH-RH antagonists.
- To discuss their therapeutic applications.
- To present recently patented compounds, formulations, and dosages.
Main Methods:
- Review of scientific literature and patent databases.
- Analysis of therapeutic applications of LH-RH antagonists.
- Summary of ongoing research and development.
Main Results:
- LH-RH antagonists have demonstrated clinical utility.
- Established applications include in vitro fertilization, benign prostatic hyperplasia, endometriosis, and hormone-dependent tumors.
- New compounds, formulations, and dosages are under investigation.
Conclusions:
- LH-RH antagonists are clinically valuable in reproductive health and oncology.
- Ongoing research focuses on developing improved peptidic and orally active non-peptidic LH-RH antagonists.
- Further advancements promise expanded therapeutic potential.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:27Hormones of the Pituitary Gland
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
01:22Birth Control Methods
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...
01:26Testosterone: Functions and Regulation
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...